SCHEMBL722560

SCHEMBL722560

c1ccc(Nc2nccs2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.59
KMT2A Q03164 4/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
NPC1 O15118 3/20 0.59
MEN1 O00255 3/20 0.59
ALDH1A1 P00352 2/20 0.59
TDP1 Q9NUW8 2/20 0.59
NFKB1 P19838 2/20 0.59
NPSR1 Q6W5P4 2/20 0.59
CYP1A2 P05177 2/20 0.59
GAA P10253 2/20 0.59
MAPK1 P28482 2/20 0.59
HSD17B10 Q99714 2/20 0.59
LMNA P02545 2/20 0.59
AURKA O14965 1/20 0.59
PIM1 P11309 1/20 0.59
CDK2 P24941 1/20 0.59
GSK3B P49841 1/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2D6 P10635 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6833454 0.98 RAB9A (0.57) RAB9AKMT2ASMN1; SMN2NPC1MEN1
Bromide SCHEMBL7502411 0.98 RAB9A (0.57) RAB9AKMT2ASMN1; SMN2NPC1MEN1
SCHEMBL27630368 0.89 PLA2G7 (0.55) RAB9AKMT2ASMN1; SMN2NPC1MEN1
SCHEMBL8906815 0.86 PLA2G7 (0.59) RAB9AKMT2ASMN1; SMN2NPC1MEN1
SCHEMBL10625612 0.84 PLA2G7 (0.51) RAB9AKMT2ASMN1; SMN2NPC1MEN1
SCHEMBL17397927 0.83 PLA2G7 (0.49) RAB9AKMT2ASMN1; SMN2NPC1MEN1
SCHEMBL9343718 0.82 NPC1 (0.57) RAB9AKMT2ASMN1; SMN2NPC1MEN1
SCHEMBL27923797 0.81 MAPT (0.53) RAB9AKMT2ASMN1; SMN2NPC1MEN1
SCHEMBL3048424 0.81 SYK (0.60) RAB9AKMT2ASMN1; SMN2NPC1MEN1
SCHEMBL11896454 0.81 PLA2G7 (0.51) RAB9AKMT2ASMN1; SMN2NPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115385868-A Synthesis and application of ClbP fluorescent probe with high selectivity recognition 湖南师范大学 2022-11-25 CN claimed
EP-1392309-B1 SUBSTITUTED PYRAZINONES, PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR LIGANDS BRISTOL MYERS SQUIBB CO (US) 2007-01-17 EP claimed
EP-0871619-B1 PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES BOEHRINGER INGELHEIM PHARMA (US) 2002-11-06 EP claimed
US-6288091-B1 COMPOUNDS SUCH AS 2,2,2-TRICHLOROETHYL N-(4-(2-AMINO-4-THIAZOLYL)-PHENYL)CARBAMATE THAT INHIBIT THE HERPES HELCASE-PRIMASE ENZYME COMPLEX BOEHRINGER INGELHEIM LTD. (CA) 2001-09-11 US claimed
EP-0871619-A1 PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 1998-10-21 EP claimed
WO-1997024343-A1 PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1997-07-10 WO claimed
JP-6056808-A None JP disclosed
CN-120271526-B Phenylaminothiazole derivative and application thereof as bactericide 安徽理工大学 2025-10-31 CN disclosed
CN-120271526-B Phenylaminothiazole derivative and application thereof as bactericide 安徽理工大学 2025-10-31 CN disclosed
CN-120271526-A Phenylaminothiazole derivative and application thereof as bactericide 安徽理工大学 2025-07-08 CN disclosed
CN-120271526-A Phenylaminothiazole derivative and application thereof as bactericide 安徽理工大学 2025-07-08 CN disclosed
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 US disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 US disclosed
US-6057451-A AMINOTHIAZOLE DERIVATIVES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2000-05-02 US disclosed
EP-0871619-A1 PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 1998-10-21 EP disclosed
WO-1997024343-A1 PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1997-07-10 WO disclosed
JP-H0656808-A N-THIAZOLYLANILINE DERIVATIVE, ITS PRODUCTION AND PEST CONTROLLING AGENT UBE IND LTD 1994-03-01 JP disclosed
EP-0192998-B1 THIAZOLYL AMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN COMBATING NON-DESIRED PLANT GROWTH BASF Aktiengesellschaft (DE) 1990-01-24 EP disclosed
US-4769062-A Thiazolylamides, their preparation, and their use for controlling undesirable plant growth BASF AKTIENGESELLSCHAFT (DE) 1988-09-06 US disclosed
EP-0192998-A2 Thiazolyl amides, process for their preparation and their use in combating non-desired plant growth BASF Aktiengesellschaft (DE) 1986-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 RAB9A 1147/4885KMT2A 2242/4885SMN1; SMN2 3816/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 RAB9A 1147/4885KMT2A 2242/4885SMN1; SMN2 3816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.